This is a highlights summary of an oral session given at the EADV Virtual Congress and presented by:

Erika Richtig, MD
Medical University of Graz
Graz, Austria

The content is produced by Infomedica, the official reporting partner of EADV Virtual Congress. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Prof. Brigitte Dréno, the scientific editor of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Caroline Robert, MD, PhD
Head Dermatology and Melanoma Research Team in U 981 INSERM
Gustave Roussy and Paris-Saclay Université
France

Caroline Robert, MD, PhD
Head Dermatology and Melanoma Research Team in U 981 INSERM
Gustave Roussy and Paris-Saclay Université 

Caroline Robert, M.D., Ph.D. is the Head of the Dermatology Service at Gustave Roussy Cancer Campus and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France and completed a research fellowship at Harvard, Brigham & Women’s hospital in Cancer Immunology and Immunotherapy. She is full Professor of Dermatology and responsible for teaching Dermatology and Dermato-Oncology in Paris-Saclay University Medicine School. Her main interests are clinical and translational Research on Melanoma involving immunotherapy and targeted therapy. She is national and international coordinator of many clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. Her research work focuses on the involvement of the control of mRNA translation in resistance to immunotherapy and targeted therapies for melanoma. The objectives are the identification of new predictive biomarkers as well as the development of new therapies to delay therapeutic resistance. She has authored more than 350 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma. She is past-president the Melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC) and is board member for the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO), the European Association of Dermato-Venereology (EADV) the French society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) and the American Association of Clinical Research (AACR).

She has received several awards and prizes including the French Legion d’Honneur in 2014, the INSERM Research Award and the Bettencourt Schueller Foudation Reasearch Award in 2015, the San Salvatore Foundation, Lugano Award in 2016, the Roy-Vaucouloux Award from the French Cancer League the Rose Lamarca Award from the French Academy of Medicine  as well as the Memorial Holst Lecture Award in 2017, the Translational Research Leopold Griffuel Award from the Association pour la Recherche sur le Cancer and the Estela Medrano Award for the Society for Melanoma Research in 2018, ESMO Woman Award and Rosen Award from the Fondation pour la Recherche Médicale in 2020. She was elected as a corresponding member of the French National Academy of Medicine in 2019

1. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. Eur J Cancer 2020;126:159–77.

2. Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol 2020;S0923-7534(20)39939.

3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival outcomes of the CheckMate 067 Phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma. Presented at ESMO 2019.

4. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017;377:1345–56.

5. Hodi FS, Chairion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1480–92.

6. Robert C, Long GV, Lartkin J, et al. 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab or nivolumab alone. Presented at ESMO 2020; #1082MO.

7. Di Giacoma AM. Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain. Presented at ESMO 2020; #1081MO.

8. da Silva IP, Ahmed T, Lo S, et al. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. Presented at ASCO 2020.

9. Postow M, Goldman DA, Shoushtari AN, et al. A Phase II study to evaluate the need for >2 doses of nivolumab + ipilimumab combination immunotherapy in patients with unresectable stage III/IV melanoma. Presented at ASCO 2020.

10. Ascierto PA, Mandala M, Ferruci PF, et al. First report of efficacy and safety from the Phase II study SECOMBIT (Sequential COMBo Immuno and Targeted therapy study). Presented at ESMO 2020; LBA#2621.

11. Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. Oncoimmunology 2018;7(9):e1468955.